The latest price target for Gecina Nom (OTCPK:GECFF) was reported by Goldman Sachs on October 15, 2021. The analyst firm set a price target for $0.00 expecting GECFF to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Gecina Nom (OTCPK:GECFF) was provided by Goldman Sachs, and Gecina Nom upgraded their buy rating.

The last upgrade for Gecina Nom happened on October 15, 2021 when Goldman Sachs raised their price target to N/A. Goldman Sachs previously had a neutral for Gecina Nom.

There is no last downgrade for Gecina Nom.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gecina Nom, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gecina Nom was filed on October 15, 2021 so you should expect the next rating to be made available sometime around October 15, 2022.

While ratings are subjective and will change, the latest Gecina Nom (GECFF) rating was a upgraded with a price target of $0.00 to $0.00. The current price Gecina Nom (GECFF) is trading at is $106.58, which is out of the analyst’s predicted range.